Products - Ovarian cancer | Topic | NICE

Showing 11 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Ovarian cancer QS update
Status:
In development
Expected publication date:
5 February 2025
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC